Sign inCreate account

Report workspace tools

NCT06663787ACTIVE_NOT_RECRUITINGanonymous

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment

Sponsor

Source record

Nagoya City University

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

HER2-positive metastatic breast cancer

Indication / condition

AI-normalized

Breast Cancer, Metastatic

Intervention

Source record

Trastuzumab (Herceptin), SIgnatera

Source & freshness

Source record

NCT ID

NCT06663787

Original source

ClinicalTrials.gov

Source last updated

May 13, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06663787

Title

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment

Sponsor

Nagoya City University

Status

ACTIVE_NOT_RECRUITING

Phase

Observational

Condition raw

Breast Cancer, Metastatic, HER2 + Breast Cancer

Condition normalized

Breast Cancer, Metastatic, HER2 + Breast Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Trastuzumab (Herceptin), SIgnatera

Target normalized

HER2-positive metastatic breast cancer

Interventions

Trastuzumab (Herceptin), SIgnatera

Public preview

Source record

This clinical trial aims to evaluate the status of circulating tumor DNA (ctDNA) in patients with HER2-positive metastatic breast cancer who have achieved a durable response to anti-HER2 treatment. The study utilizes the Signatera™ ctDNA assay to assess minimal residual disease (MRD) and explore potential new therapeutic strategies, including the possibility of de-escalating treatment in ctDNA-negative patients.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06663787

Status

ACTIVE_NOT_RECRUITING

Phase

Observational

Sponsor

Nagoya City University

Executive brief

Investment-Ready Snapshot

This clinical trial aims to evaluate the status of circulating tumor DNA (ctDNA) in patients with HER2-positive metastatic breast cancer who have achieved a durable response to anti-HER2 treatment. The study utilizes the Signatera™ ctDNA assay to assess minimal residual disease (MRD) and explore potential new therapeutic strategies, including the possibility of de-escalating treatment in ctDNA-negative patients.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 13, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06663787

Indication

Breast Cancer, Metastatic

Modality

monoclonal antibody

Target

HER2-positive metastatic breast cancer

Intervention

Trastuzumab (Herceptin), SIgnatera

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.